Theresa E. Baker

Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Francois Gonzalvez, Sylvie Vincent, Theresa E. Baker et al. · Cancer Discovery · 2021 · 188 citations · Full text

Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors

Theresa E. Baker, Sujata Nerle, Justin R. Pritchard et al. · Oncotarget · 2015 · 79 citations · Full text

Targeting <i>HER2</i> Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Han Han, Shuai Li, Ting Chen et al. · Cancer Research · 2021 · 54 citations · Full text

Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

Francois Gonzalvez, Xiaotian Zhu, Wei‐Sheng Huang et al. · Cancer Research · 2016 · 29 citations

Her2 Variants, Her2 Exon 20, Molecular Biology +17

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer

Wei‐Sheng Huang, Feng Li, Yongjin Gong et al. · Bioorganic & Medicinal Chemistry Letters · 2022 · 21 citations · Full text

Egfr Inhibitors, Tumor Biology, Oncology +17